Real Money authors - Bruce Kamich

Bruce Kamich

Bruce Kamich is TheStreet's in-house technical analyst with a 43 year career with a number of bulge bracket firms like Morgan Stanley, Smith Barney Harris Upham, and Merrill Lynch. Along the way he accumulated knowledge about the fundamentals of the commodity markets, interest rates, equities and ETFs. 

In addition to writing for Kamich has been teaching technical analysis at Baruch College for the past twenty years.

Kamich was one of the earliest Chartered Market Technicians  or CMTs, a professional designation similar to the CFA title. He has authored two books on charting and technical analysis - "How Technical Analysis Works"  and "Chart Patterns." He is a two-time past president of the Market Technicians Association (now called the CMTA), the professional organization for chartists worldwide. He was also the president of the Market Technicians Association Educational Foundation (
Email Bruce Kamich

Recent Articles By The Author

Investors Should 'Beam' Themselves Up and Away From This Biotech

Take profits here and now on Beam Therapeutics.

CRISPR Therapeutics Has Soared in Just a Few Weeks - What to Do Now

This is a time to nail down profits.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Time to Nail Down Some Profits on Halliburton

Our latest technical analysis and trading strategy for the oil services stock.

High Flying TG Therapeutics Needs a Period of Consolidation

Let's review the charts and indicators.

Zoetis Could Rally Further After Some More Sideways Consolidation

Buyers will need to be patient.

Nutrien Has Rallied Into Chart Resistance

Let's review the charts and indicators.

Why I'm Souring on Lemonade

LMND shares have tripled in less than two months

Fiat Chrysler Shares Might Skid Sideways or Into a Correction

The charts show a shift down through this quarter and then revving up later in Q2.

Pacific Biosciences Reaches Our Price Target: Now What?

Let's check out the charts and technical indicators.

Email sent

Thank you, your email to has been sent successfully.


We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight